Primary Open-Angle Glaucoma
Definition
- Primary open‑angle glaucoma (POAG) is a chronic, progressive optic neuropathy characterized by an open anterior chamber angle, elevated intra‑ocular pressure (IOP) in most cases, and irreversible visual field loss.
Epidemiology
- POAG is the most common form of glaucoma worldwide, accounting for about 70 % of all glaucoma cases.
- Prevalence increases with age: ~2 % of people >40 years and >5 % of those >70 years are affected.
- It is more common in African‑derived populations (up to 8 % prevalence) and less common in Asian populations (≈1 %).
- Family history confers a 4‑ to 9‑fold increased risk, indicating a strong genetic component.
Aetiology (Risk Factors)
- Age: risk rises sharply after the fifth decade.
- Elevated IOP: IOP >21 mm Hg is the most important modifiable risk factor; each 1 mm Hg rise increases risk ≈10 %.
- Family history: first‑degree relatives have a higher likelihood of developing POAG.
- Race: African ancestry carries the highest risk; Asian ancestry carries a lower risk.
- Myopia: moderate to high myopia (>−3 D) is associated with increased POAG risk.
- Systemic factors: hypertension, diabetes mellitus, and low cerebrospinal fluid pressure may contribute.
Pathophysiology
- Impaired aqueous outflow: The trabecular meshwork (TM) and Schlemm’s canal become dysfunctional, leading to reduced drainage of aqueous humor from the anterior chamber.
- Extracellular matrix (ECM) remodeling: Accumulation of ECM material in the TM narrows outflow pathways; cytokines such as TGF‑β2 are implicated.
- Mechanical stress: Elevated IOP exerts posteriorly directed force on the lamina cribrosa, causing axonal compression and interruption of retinal ganglion cell (RGC) transport.
- Neurodegeneration: RGC apoptosis occurs via excitotoxicity (excess glutamate), oxidative stress, mitochondrial dysfunction, and impaired neurotrophic support.
- Vascular dysregulation: Reduced ocular perfusion pressure may exacerbate optic nerve head ischemia, especially in normal‑tension glaucoma (a subtype of POAG).
Clinical Features
- Asymptomatic early stage: Most patients have no symptoms until significant visual field loss occurs.
- Peripheral vision loss: Insidious, concentric constriction of the visual field, often first detected on automated perimetry.
- Tunnel vision: Advanced disease leads to a central island of vision.
- Optic disc changes:
- Increased cup‑to‑disc ratio (≥0.6 or asymmetry >0.2 between eyes).
- Notching of the neuroretinal rim, especially inferior and superior sectors.
- Peripapillary retinal nerve fiber layer (RNFL) thinning on OCT.
- No pain, redness, or photophobia: Distinguishes POAG from acute angle‑closure glaucoma.
Investigations
| Test | What it evaluates | Key findings in POAG |
|---|---|---|
| Tonometry (Goldmann applanation) | Intra‑ocular pressure measurement | IOP ≥21 mm Hg in most patients; however, normal‑tension POAG may have IOP ≤21 mm Hg |
| Gonioscopy | Anterior chamber angle assessment | Open angle (Schaffer grade III–IV) without peripheral anterior synechiae |
| Ophthalmoscopy (fundus exam) | Optic nerve head appearance | Enlarged optic cup, rim thinning, disc hemorrhages |
| Automated perimetry (Humphrey 24‑2) | Visual field mapping | Nasal step, arcuate scotoma, or generalized depression |
| Optical coherence tomography (OCT) | RNFL thickness and ganglion cell complex | Sectoral RNFL loss correlating with visual field defects |
| Pachymetry | Central corneal thickness (CCT) | Thin cornea (<520 µm) predicts higher risk of progression despite similar IOP |
| Family screening | Genetic predisposition | First‑degree relatives screened with IOP, optic disc, and visual fields |
Management (Current Guidelines – AAO Preferred Practice Pattern 2024)
1. Target IOP
- Definition: IOP level at which further optic nerve damage is unlikely.
- Goal: Reduce baseline IOP by at least 20‑30 % or to ≤15 mm Hg, whichever is lower, depending on disease severity.
2. First‑line Pharmacologic Therapy
| Drug class | Mechanism | Typical dosing | Common side effects |
|---|---|---|---|
| Prostaglandin analogues (e.g., latanoprost, bimatoprost) | Increase uveoscleral outflow | One drop nightly | Conjunctival hyperemia, eyelash growth, iris pigmentation |
| Beta‑blockers (e.g., timolol) | Decrease aqueous production | One drop BID or nightly | Bradycardia, bronchospasm, fatigue |
| α2‑agonists (e.g., brimonidine) | Reduce production and increase outflow | One drop TID | Dry mouth, fatigue, allergic conjunctivitis |
| Carbonic anhydrase inhibitors (e.g., dorzolamide) | Decrease aqueous production | One drop BID | Punctate keratitis, bitter taste |
- Preferred initial agent: Prostaglandin analogue because of once‑daily dosing and superior IOP‑lowering efficacy.
3. Combination Therapy
- If target IOP not achieved with a single agent, add a second drug from a different class (e.g., prostaglandin + beta‑blocker). Fixed‑combination drops improve adherence.
4. Laser Therapy
- Selective laser trabeculoplasty (SLT): 532 nm laser applied to 180‑360° of trabecular meshwork; lowers IOP by 20‑30 % and can be repeated. First‑line for patients intolerant to drops or as adjunct after medication failure.
- Argon laser trabeculoplasty (ALT): Older technique, less commonly used due to higher inflammation risk.
5. Surgical Options (when medical/laser control inadequate)
- Trabeculectomy: Creation of a filtering bleb to divert aqueous humor; gold standard surgery.
- Glaucoma drainage devices (e.g., Ahmed, Baerveldt): Implanted tubes that shunt fluid to an external plate; used in refractory or neovascular glaucoma.
- Minimally invasive glaucoma surgery (MIGS): iStent, Hydrus, Trabectome; lower complication profile, suitable for mild‑moderate disease.
6. Follow‑up and Monitoring
- IOP checks: Every 4–6 weeks after initiating therapy, then every 3–6 months once stable.
- Visual field testing: Every 6–12 months; more frequent if progression suspected.
- OCT RNFL analysis: Annually or sooner if visual field changes occur.
Complications
- Progressive visual field loss: Leads to irreversible blindness if untreated.
- Surgical complications: Bleb leak, hypotony, infection (blebitis, endophthalmitis), cataract formation after trabeculectomy.
- Medication side effects: Systemic β‑blocker absorption causing bradycardia or asthma exacerbation; prostaglandin‑induced uveitis.
High‑Yield Exam Points
- POAG is a chronic, painless, optic neuropathy with an open anterior chamber angle.
- IOP is the only modifiable risk factor; aim for ≥20 % reduction from baseline.
- Prostaglandin analogues are the first‑line drug due to efficacy and once‑daily dosing.
- SLT can be used as a first‑line or adjunctive therapy and may delay or replace surgery.
- Target IOP is individualized: mild disease → 20 % reduction; moderate–severe → ≤15 mm Hg.
- Family screening is essential because of the strong hereditary component.
- Disc hemorrhage on ophthalmoscopy is a red flag for rapid progression.
- Normal‑tension glaucoma is a subtype of POAG with IOP ≤21 mm Hg; vascular factors are more prominent.
- CCT influences IOP measurement; thin corneas underestimate true IOP and predict faster progression.
Practice questions
1. A 58‑year‑old African‑American woman presents for routine eye examination. Her IOP is 24 mm Hg bilaterally, optic discs show a cup‑to‑disc ratio of 0.7 with inferior rim thinning, and Humphrey visual field reveals an early nasal step. Which of the following is the most appropriate first‑line therapy?
- A) Timolol eye drops
- B) Latanoprost eye drops
- C) Argon laser trabeculoplasty
- D) Trabeculectomy
Answer: B — prostaglandin analogue (latanoprost) is the preferred first‑line medication for POAG.
2. In a patient with POAG, the target IOP is set at 14 mm Hg. The current IOP on maximal tolerated medical therapy is 18 mm Hg. Which intervention is recommended next according to the 2024 AAO guidelines?
- A) Add a second topical medication
- B) Perform selective laser trabeculoplasty (SLT)
- C) Schedule immediate trabeculectomy
- D) Observe and repeat IOP measurement in 6 months
Answer: B — SLT is recommended when target IOP is not achieved with maximal medical therapy before proceeding to surgery.
3. A 70‑year‑old man with POAG has a central corneal thickness of 500 µm. Which statement best reflects the clinical significance of this finding?
- A) His IOP readings are likely overestimated, reducing the need for treatment.
- B) Thin cornea predisposes him to faster disease progression despite similar measured IOP.
- C) Corneal thickness does not affect glaucoma management.
- D) Thick corneas are associated with higher risk of optic disc hemorrhage.
Answer: B — a thin cornea underestimates true IOP and is an independent risk factor for faster progression.
Want to master Primary Open-Angle Glaucoma?
Ask MEDOST anything about it, take a quiz, or practise ECG strips — free.
Study Primary Open-Angle Glaucoma on MEDOSTMore in Ophthalmology
AI-assisted study material for exam revision. Always confirm with standard textbooks and current guidelines; not medical advice.